http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 20 Oct 2026 09:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/ScionxBio+Announces+Collaboration+to+Develop+Long-Acting+xRNA+Therapeutics/27207955.html <p> CAMBRIDGE, England--(BUSINESS WIRE)-- ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi (EURONEXT: SAN) (NASDAQ: SNY) to develop and commercialize extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio’s proprietary TERA® platform.</p><p>This agreement brings together the global expertise of Sanofi’s mRNA Center of Excellence, with ScionxBio’s TERA platform. This collaboration represents a critical step in http://www.streetinsider.com/Press+Releases/ScionxBio+Announces+Collaboration+to+Develop+Long-Acting+xRNA+Therapeutics/27207955.html Tue, 20 Oct 2026 09:10:00 -0400 SNY http://www.streetinsider.com/Business+Wire/ScionxBio+Announces+Collaboration+to+Develop+Long-Acting+xRNA+Therapeutics/27207955.html <p> CAMBRIDGE, England--(BUSINESS WIRE)-- ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi (EURONEXT: SAN) (NASDAQ: SNY) to develop and commercialize extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio’s proprietary TERA® platform.</p><p>This agreement brings together the global expertise of Sanofi’s mRNA Center of Excellence, with ScionxBio’s TERA platform. This collaboration represents a critical step in http://www.streetinsider.com/Business+Wire/ScionxBio+Announces+Collaboration+to+Develop+Long-Acting+xRNA+Therapeutics/27207955.html Tue, 20 Oct 2026 09:10:00 -0400 SNY http://www.streetinsider.com/Intl+Ratings/Sanofi+%28SAN%3AFP%29+%28SNY%29+PT+Lowered+to+EUR75+at+RBC+Capital/27194729.html RBC Capital analyst Trung Huynh lowered the price target on Sanofi (SAN:FP) (NASDAQ: SNY) to EUR75.00 (from EUR80.00) while maintaining a Sector Perform rating. http://www.streetinsider.com/Intl+Ratings/Sanofi+%28SAN%3AFP%29+%28SNY%29+PT+Lowered+to+EUR75+at+RBC+Capital/27194729.html Fri, 16 Oct 2026 02:16:35 -0400 SNY http://www.streetinsider.com/Analyst+PT+Change/Sanofi+%28SAN%3AFP%29+%28SNY%29+PT+Lowered+to+EUR75+at+RBC+Capital/27194729.html RBC Capital analyst Trung Huynh lowered the price target on Sanofi (SAN:FP) (NASDAQ: SNY) to EUR75.00 (from EUR80.00) while maintaining a Sector Perform rating. http://www.streetinsider.com/Analyst+PT+Change/Sanofi+%28SAN%3AFP%29+%28SNY%29+PT+Lowered+to+EUR75+at+RBC+Capital/27194729.html Fri, 16 Oct 2026 02:16:35 -0400 SNY http://www.streetinsider.com/Intl+Ratings/Sanofi+%28SAN%3AFP%29+%28SNY%29+PT+Lowered+to+EUR75+at+RBC+Capital/27194729.html RBC Capital analyst Trung Huynh lowered the price target on Sanofi (SAN:FP) (NASDAQ: SNY) to EUR75.00 (from EUR80.00) while maintaining a Sector Perform rating. http://www.streetinsider.com/Intl+Ratings/Sanofi+%28SAN%3AFP%29+%28SNY%29+PT+Lowered+to+EUR75+at+RBC+Capital/27194729.html Fri, 16 Oct 2026 02:16:35 -0400 SNY http://www.streetinsider.com/Analyst+PT+Change/Sanofi+%28SAN%3AFP%29+%28SNY%29+PT+Lowered+to+EUR75+at+RBC+Capital/27194729.html RBC Capital analyst Trung Huynh lowered the price target on Sanofi (SAN:FP) (NASDAQ: SNY) to EUR75.00 (from EUR80.00) while maintaining a Sector Perform rating. http://www.streetinsider.com/Analyst+PT+Change/Sanofi+%28SAN%3AFP%29+%28SNY%29+PT+Lowered+to+EUR75+at+RBC+Capital/27194729.html Fri, 16 Oct 2026 02:16:35 -0400 SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/New+Coverage/Wolfe+Research+Starts+Sanofi+%28SNY%29+at+Peerperform/27168515.html <p>Wolfe Research analyst Alexandria Hammond initiates coverage on Sanofi (NASDAQ: SNY) with a Peerperform rating.</p> <p>For an analyst ratings summary and ratings history on Sanofi <a href="http://www.streetinsider.com/rating_history.php?q=SNY">click here</a>. For more ratings news on Sanofi <a href="http://www.streetinsider.com/stock_lookup_news.php?q=SNY&amp;type=analyst">click here</a>.</p> <p>Shares of Sanofi closed at $40.23 yesterday.</p> http://www.streetinsider.com/New+Coverage/Wolfe+Research+Starts+Sanofi+%28SNY%29+at+Peerperform/27168515.html Fri, 09 Oct 2026 05:37:25 -0400 SNY http://www.streetinsider.com/Press+Releases/Sanofi+and+2026+NBA+Champion+Karl-Anthony+Towns+team+up+to+raise+awareness+of+COVID-19+vaccination+with+NUVAXOVID%C2%AE/27140385.html <div class="xn-content"> <ul type="disc"> <li>The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA Champion <person>Karl-Anthony Towns</person> brings his personal experience with COVID-19 to encourage eligible people, especially those at increased risk, to learn about their vaccination options</li> <li>Towns shares why protecting his health remains http://www.streetinsider.com/Press+Releases/Sanofi+and+2026+NBA+Champion+Karl-Anthony+Towns+team+up+to+raise+awareness+of+COVID-19+vaccination+with+NUVAXOVID%C2%AE/27140385.html Fri, 02 Oct 2026 11:57:00 -0400 SNY http://www.streetinsider.com/PRNewswire/Sanofi+and+2026+NBA+Champion+Karl-Anthony+Towns+team+up+to+raise+awareness+of+COVID-19+vaccination+with+NUVAXOVID%C2%AE/27140385.html <div class="xn-content"> <ul type="disc"> <li>The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA Champion <person>Karl-Anthony Towns</person> brings his personal experience with COVID-19 to encourage eligible people, especially those at increased risk, to learn about their vaccination options</li> <li>Towns shares why protecting his health remains http://www.streetinsider.com/PRNewswire/Sanofi+and+2026+NBA+Champion+Karl-Anthony+Towns+team+up+to+raise+awareness+of+COVID-19+vaccination+with+NUVAXOVID%C2%AE/27140385.html Fri, 02 Oct 2026 11:57:00 -0400 SNY http://www.streetinsider.com/Analyst+PT+Change/Regeneron+Pharma+%28REGN%29+PT+Raised+to+%24930+at+Jefferies/27134381.html <p>Jefferies analyst Akash Tewari raised the price target on Regeneron Pharma (NASDAQ: REGN) to $930.00 (from $870.00) while maintaining a Buy rating.</p><p>The analyst comments "REGN and SNY expanded their partnership around 4 next-gen type-2 inflammation assets, w/ REGN receiving $1B upfront + up to $7B milestones and 50/50 global economics. We see the deal as net +'ve for the co given better economics vs piror Dupi collab, a proven development & commercial playbook, sufficient time before Dupi LOE, and upside from lunsekimig optionality. Bottom line: REGN and SNY announced an expanded collaboration covering 4 next-gen antibodies (IL-13, IL-4xIL-13 bispecific, IL-4 http://www.streetinsider.com/Analyst+PT+Change/Regeneron+Pharma+%28REGN%29+PT+Raised+to+%24930+at+Jefferies/27134381.html Thu, 01 Oct 2026 12:43:33 -0400 REGN SNY http://www.streetinsider.com/Analyst+Comments/Regeneron+Pharma+%28REGN%29+PT+Raised+to+%24930+at+Jefferies/27134381.html <p>Jefferies analyst Akash Tewari raised the price target on Regeneron Pharma (NASDAQ: REGN) to $930.00 (from $870.00) while maintaining a Buy rating.</p><p>The analyst comments "REGN and SNY expanded their partnership around 4 next-gen type-2 inflammation assets, w/ REGN receiving $1B upfront + up to $7B milestones and 50/50 global economics. We see the deal as net +'ve for the co given better economics vs piror Dupi collab, a proven development & commercial playbook, sufficient time before Dupi LOE, and upside from lunsekimig optionality. Bottom line: REGN and SNY announced an expanded collaboration covering 4 next-gen antibodies (IL-13, IL-4xIL-13 bispecific, IL-4 http://www.streetinsider.com/Analyst+Comments/Regeneron+Pharma+%28REGN%29+PT+Raised+to+%24930+at+Jefferies/27134381.html Thu, 01 Oct 2026 12:43:33 -0400 REGN SNY http://www.streetinsider.com/Analyst+PT+Change/Regeneron+Pharma+%28REGN%29+PT+Raised+to+%24930+at+Jefferies/27134381.html <p>Jefferies analyst Akash Tewari raised the price target on Regeneron Pharma (NASDAQ: REGN) to $930.00 (from $870.00) while maintaining a Buy rating.</p><p>The analyst comments "REGN and SNY expanded their partnership around 4 next-gen type-2 inflammation assets, w/ REGN receiving $1B upfront + up to $7B milestones and 50/50 global economics. We see the deal as net +'ve for the co given better economics vs piror Dupi collab, a proven development & commercial playbook, sufficient time before Dupi LOE, and upside from lunsekimig optionality. Bottom line: REGN and SNY announced an expanded collaboration covering 4 next-gen antibodies (IL-13, IL-4xIL-13 bispecific, IL-4 http://www.streetinsider.com/Analyst+PT+Change/Regeneron+Pharma+%28REGN%29+PT+Raised+to+%24930+at+Jefferies/27134381.html Thu, 01 Oct 2026 12:43:33 -0400 REGN SNY http://www.streetinsider.com/Analyst+Comments/Regeneron+Pharma+%28REGN%29+PT+Raised+to+%24930+at+Jefferies/27134381.html <p>Jefferies analyst Akash Tewari raised the price target on Regeneron Pharma (NASDAQ: REGN) to $930.00 (from $870.00) while maintaining a Buy rating.</p><p>The analyst comments "REGN and SNY expanded their partnership around 4 next-gen type-2 inflammation assets, w/ REGN receiving $1B upfront + up to $7B milestones and 50/50 global economics. We see the deal as net +'ve for the co given better economics vs piror Dupi collab, a proven development & commercial playbook, sufficient time before Dupi LOE, and upside from lunsekimig optionality. Bottom line: REGN and SNY announced an expanded collaboration covering 4 next-gen antibodies (IL-13, IL-4xIL-13 bispecific, IL-4 http://www.streetinsider.com/Analyst+Comments/Regeneron+Pharma+%28REGN%29+PT+Raised+to+%24930+at+Jefferies/27134381.html Thu, 01 Oct 2026 12:43:33 -0400 REGN SNY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Sanofi++++++++++++++++++++For%3A+Oct+01/27134186.html si-local-file:///var/storage/secattach/20261001/27134186.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Sanofi++++++++++++++++++++For%3A+Oct+01/27134186.html Thu, 01 Oct 2026 12:09:00 -0400 SNY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Sanofi++++++++++++++++++++For%3A+Sep+17/27072350.html si-local-file:///var/storage/secattach/20260917/27072350.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Sanofi++++++++++++++++++++For%3A+Sep+17/27072350.html Thu, 17 Sep 2026 06:09:00 -0400 SNY